CRISPR Therapeutics AG (CRSP)
51.14
-2.46
(-4.60%)
USD |
NASDAQ |
May 10, 16:00
51.37
+0.24
(+0.46%)
After-Hours: 19:20
CRISPR Therapeutics Profit Margin (Quarterly): 44.67% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 44.67% |
September 30, 2023 | |
June 30, 2023 | -111.1% |
March 31, 2023 | -53.06% |
December 31, 2022 | -1.84M% |
September 30, 2022 | -185.7K% |
June 30, 2022 | -117.6K% |
March 31, 2022 | -100.7K% |
December 31, 2021 | -1.14K% |
September 30, 2021 | -38.65K% |
June 30, 2021 | 84.34% |
March 31, 2021 | -56.02K% |
December 31, 2020 | -55.17K% |
September 30, 2020 | -62.46K% |
June 30, 2020 | -181.0K% |
March 31, 2020 | -44.41K% |
December 31, 2019 | 39.66% |
Date | Value |
---|---|
September 30, 2019 | 65.32% |
June 30, 2019 | -16.89K% |
March 31, 2019 | -14.76K% |
December 31, 2018 | -41.38K% |
September 30, 2018 | -9.01K% |
June 30, 2018 | -3.53K% |
March 31, 2018 | -2.08K% |
December 31, 2017 | 0.44% |
September 30, 2017 | -1.04K% |
June 30, 2017 | -623.0% |
March 31, 2017 | -794.5% |
December 31, 2016 | |
September 30, 2016 | -948.6% |
June 30, 2016 | -2.16K% |
March 31, 2016 | -1.77K% |
December 31, 2015 | -4.97K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-1.84M%
Minimum
Dec 2022
84.34%
Maximum
Jun 2021
-150.1K%
Average
-41.53K%
Median
Profit Margin (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | 40.87% |
Intellia Therapeutics Inc | -- |
Novartis AG | 22.18% |
AC Immune SA | -32.05% |
Addex Therapeutics Ltd | -1.86K% |
Profit Margin (Quarterly) Related Metrics
Return on Equity | -8.39% |
Return on Assets | -6.98% |
Return on Invested Capital | -8.39% |
Gross Profit Margin (Quarterly) | 90.00% |
Operating Margin (Quarterly) | 34.79% |
Return on Net Operating Assets | -41.67% |